Clinical Research Directory

Inclusion Criteria: * To sign the study informed consent form approved by the corresponding authorities. * Men and women enrolled in the ALFA project (STUDY 45-65 FPM/2012). * Participants with a cerebral MRI (magnetic resonance imaging) not suggestive of radiological incidental findings constituting an exclusion criterion. * Cognition within psychometrically normal ranges: MMSE (Mini Mental State Examination ≥26 and Semantic Fluency (animals) ≥12. * Score of 0 in the CDR scale (Clinical Dementia Rating). * Good knowledge of the language and being literate. * Female participants should be post-menopausal or present a negative pregnancy test at the moment of PET acquisition. Exclusion Criteria: * Present cognitive impairment. * Presence of clinically relevant psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV-TR) criteria: major depressive disorder, generalized anxiety disorder, schizophrenia or bipolar disorder. * Individuals with visual and/or hearing impairment. * History of encephalitis, ictus or seizures excluding feverish convulsions during childhood. * Severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumor (metastasis/brain cancer) as verified by magnetic resonance imaging (MRI). * Any contraindication to MRI acquisition, (i.e., metal implants) or phobia to performing the scan as determined by the onsite physician. * Previous participation in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and/or administration of a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study.